Larimar Therapeutics
Market cap $313M 104.6M shares (10-Q, Nov 10, 2026) × $2.99 close Nov 17, 2026
Most recent annual filing: 2026-03-15
- fill-and-finish manufacturing update2H 2026/1H 2027fill-and-finish manufacturing update, 2H 2026/1H 2027, routine
- corporate financing2H 2026/1H 2027corporate financing, 2H 2026/1H 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (1 active programs)
Technology platforms
CPP
Cell penetrating peptide (CPP) technology platform enabling therapeutic molecules to cross cell membranes and reach intracellular targets, including mitochondria; focused on rare and orphan diseases characterized by deficiencies in or alterations of intracellular content or activity
intracellular delivery platform
Fusion protein delivery platform enabling intracellular delivery of bioactive compounds; focus on rare diseases characterized by deficiencies in intracellular bioactive compounds.
Capital (as filed)
- Cash
- $77.0M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $51.7M Sep 30, 2026
- Operating cash flow
- −$31.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $129M cash, runway late Q2 2027 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (7)
- 2026-11-17 UPDATE: Larimar (LRMR) - The 483 Is Still Open, and RTW Walked In
- 2026-11-10 UPDATE: Larimar (LRMR) - The BLA Is In, the Runway Got Shorter 🔒 Paid
- 2026-08-05 UPDATE: Larimar (LRMR) - The Form 483 Buried in the 10-Q 🔒 Paid
- 2026-06-30 UPDATE: Larimar (LRMR) - The BLA Clock Starts 🔒 Paid
- 2026-03-21 UPDATE: Larimar (LRMR) - The $63 Million Tell 🔒 Paid
- 2026-02-28 UPDATE: Larimar (LRMR) - The FDA Blinks, Larimar Squeezes, and the Dilution Gap Closes 🔒 Paid
- 2026-01-11 Larimar Therapeutics (LRMR): Scientific Deep Dive for Nomlabofusp and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (7 calls)
Every verdict Biotech Distilled has published on Larimar Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-01-11 Watch Larimar Therapeutics (LRMR): Scientific Deep Dive for Nomlabofusp and Pipeline Products Science is real and regulatory path is promising, but the anaphylaxis safety profile requires monitoring before committing capital; wait for Q1 2026 modified dosing regimen data.
- 2026-02-28 Buy core UPDATE: Larimar (LRMR) - The FDA Blinks, Larimar Squeezes, and the Dilution Gap Closes FDA Breakthrough Therapy Designation effectively removes the tail-risk of a clinical hold on safety, and the $107M secondary offering closes the dilution gap, providing a clear FDA-endorsed path to June 2026 BLA filing.
- 2026-03-21 Buy core UPDATE: Larimar (LRMR) - The $63 Million Tell The $63M deployment toward commercial-scale manufacturing confirms management's conviction that the June 2026 BLA submission and subsequent approval are probable events.
- 2026-06-30 Buy core UPDATE: Larimar (LRMR) - The BLA Clock Starts Module 1 of the rolling BLA is filed, FDA minutes endorse the surrogate endpoint, naïve-patient anaphylaxis rate collapsed to ~9% under titration protocol, and the stock at $3.20 represents a window versus the improving science.
- 2026-08-05 Hold UPDATE: Larimar (LRMR) - The Form 483 Buried in the 10-Q All timelines held and runway extended, but a named Form 483 at the fill-and-finish plant on the BLA critical path and going-concern language shift the risk profile; existing holders should hold rather than chase at $4.11.
- 2026-11-10 Buy core UPDATE: Larimar (LRMR) - The BLA Is In, the Runway Got Shorter BLA is fully submitted on schedule with FDA endorsement of the surrogate endpoint intact, but runway shrank to late Q2 2027 and launch slipped to Q3 2027, making financing the primary near-term risk rather than biology.
- 2026-11-17 Buy core UPDATE: Larimar (LRMR) - The 483 Is Still Open, and RTW Walked In BLA is in with priority review requested and RTW now holds 5.6%, but the Form 483 remains open and explicitly tied to approval timing while ATM dilution and a late-Q2 2027 runway keep financing risk elevated.
- Long call · opened Mar 2, 2026 at $5.23 · -42.8% vs XBI +14.8% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (2 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“We plan to initiate dosing of the first patient in the third quarter of 2026.”
matched to nomlabofusp · regulatory submission
-
-
-
“We plan to initiate dosing of the first patient in the third quarter of 2026.”
matched to nomlabofusp · trial initiation
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (25)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026ReleaseLarimar Therapeutics Reports Third Quarter 2026 Financial and Business Update→ BD updateSummary on the 8-K
- Nov 16, 20268-KCurrent report: results of operations · EX-99.1→ BD updateLarimar's Q3 earnings confirm the BLA is in and the milestone calendar is set — but the runway just shrank to late Q2 2027, the fill-and-finish Form 483 language hardened, and RTW Investments just disclosed a fresh 5.6% stake. Here's where things stand heading into the FDA acceptance window.
- Nov 16, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 9, 2026ReleaseLarimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia→ BD updateSummary on the 8-K
- Nov 9, 20268-KCurrent report: results of operations, other events · EX-99.1→ BD updateLarimar completed its rolling BLA submission for nomlabofusp after the close today — the milestone I've called "The Big One" since the original deep dive — with FDA acceptance targeted for early 2027 and Q3 cash at $128.7M as the runway clock ticks toward a mid-2027 approval decision.
- Nov 5, 2026ReleaseLarimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
- Nov 4, 2026ReleaseLarimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
- Sep 29, 2026ReleaseLarimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
- Sep 29, 20268-KCurrent report: officer / director change
- Aug 4, 2026ReleaseLarimar Therapeutics Reports Second Quarter 2026 Financial and Business UpdateBD extracted 1 program update from this document → LRMR pipeline
- Aug 4, 20268-KCurrent report: results of operations, other events · EX-99.1
- Aug 4, 202610-QQuarterly report
- Jun 29, 2026ReleaseLarimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s AtaxiaBD extracted 2 program updates from this document → LRMR pipeline
- Jun 29, 20268-KCurrent report: other events · EX-99.1
- Jun 26, 2026ReleaseLarimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
- May 19, 20268-KCurrent report: shareholder vote
- May 14, 2026ReleaseLarimar Therapeutics Reports First Quarter 2026 Financial and Business Update
- May 14, 20268-KCurrent report: results of operations, other events · EX-99.1
- May 14, 202610-QQuarterly report
- Apr 30, 2026ReleaseLarimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia
- Apr 20, 2026DEF 14AProxy statement
- Mar 19, 20268-KCurrent report: results of operations · EX-99.1
- Mar 19, 202610-KAnnual report
- Mar 9, 20268-KCurrent report: other events · EX-99.1
- Mar 2, 2026SCHEDULE 13D/A13D amendment
7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13GPassive >5% holder (13G)→ BD updateSummary on the 8-K
- Nov 16, 2026S-8Employee plan registration→ BD updateSummary on the 8-K
- May 14, 2026SCHEDULE 13G/A13G amendment
- Apr 30, 2026SCHEDULE 13G/A13G amendment
- Apr 20, 2026ARSAnnual report to shareholders
- Apr 10, 2026PRE 14APRE 14A
- Mar 19, 2026S-8Employee plan registration